Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 172

Showing 1-25 of 172 citing articles:

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Chunrong Yang, Yuchen Yang, Yujie Li, et al.
Journal of the American Chemical Society (2022) Vol. 145, Iss. 1, pp. 385-391
Closed Access | Times Cited: 73
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 13
PROTAC Prodrug‐Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer
Shunan Zhang, Yi Lai, Jiaxing Pan, et al.
Advanced Materials (2024) Vol. 36, Iss. 23
Closed Access | Times Cited: 12
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Yanhua Chen, Qianqian Zhou, William Hankey, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 56
BET proteins: Biological functions and therapeutic interventions
Jiawei Guo, Qingquan Zheng, Yong Peng
Pharmacology & Therapeutics (2023) Vol. 243, pp. 108354-108354
Closed Access | Times Cited: 32
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 32
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 28
Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy
Ruoxi Sang, Renming Fan, Aohua Deng, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8464-8483
Closed Access | Times Cited: 26
Microtubule‐targeting agents for cancer treatment: Seven binding sites and three strategies
Xingyu Wang, Benoı̂t Gigant, Xi Zheng, et al.
MedComm – Oncology (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 25
Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells
Han Wang, Chao Wang, Bingru Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115343-115343
Closed Access | Times Cited: 23
Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang, Bo Kong, Zhaohong Zhu, et al.
Molecular Diversity (2023) Vol. 28, Iss. 1, pp. 309-333
Open Access | Times Cited: 21
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 20
Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 776-785
Closed Access | Times Cited: 20
CircRNF10 triggers a positive feedback loop to facilitate progression of glioblastoma via redeploying the ferroptosis defense in GSCs
Chengbin Wang, Minjie Zhang, Yingliang Liu, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 20
Chaperone‐mediated autophagy: Molecular mechanisms, biological functions, and diseases
Ruchen Yao, Jun Shen
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 19
Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs
Ninglin Chen, Zeyu Zhang, Xin Liu, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 15, pp. 10753-10766
Closed Access | Times Cited: 10
A PROTAC Augmenter for Photo‐Driven Pyroptosis in Breast Cancer
Daipeng Huang, Yang Zou, Haiqiao Huang, et al.
Advanced Materials (2024) Vol. 36, Iss. 21
Closed Access | Times Cited: 9
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5351-5372
Closed Access | Times Cited: 9
Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 9
Targeting mitochondrial quality control: new therapeutic strategies for major diseases
Weilong Hong, He Huang, Xue Zeng, et al.
Military Medical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 9
From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
Siqi Wang, Fuchu He, Chunyan Tian, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 100-100
Open Access | Times Cited: 7
Simplifying Access to Targeted Protein Degraders via Nickel Electrocatalytic Cross‐Coupling
Philipp Neigenfind, Luca Massaro, Áron Péter, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 16
Closed Access | Times Cited: 7
Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor
Shipra Malik, Sai Pallavi Pradeep, Vikas Kumar, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 1, pp. 101354-101354
Open Access | Times Cited: 6
Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy
Mengxia Xu, Yuyang Yun, Changjun Li, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 13, pp. 3240-3248
Closed Access | Times Cited: 6
Click Chemistry-Based Nanomaterial Modification for Cancer Targeting: A Review
Jiaming Shi, Wenjun Fu, Qing Zou, et al.
ACS Applied Nano Materials (2025)
Closed Access
Page 1 - Next Page

Scroll to top